Highlights
- In the phase 3a REIMAGINE 1 study, once-weekly cagrilintide-semaglutide (CagriSema) produced clinically large reductions in both HbA1c and bodyweight in adults with early type 2 diabetes inadequately controlled with diet and exercise.
- The higher-dose regimen (2.4 mg cagrilintide plus 2.4 mg semaglutide) reduced HbA1c by an estimated 1.8 percentage points and bodyweight by 13.8% at week 40, both clearly superior to placebo.
- The safety profile was dominated by mostly mild-to-moderate gastrointestinal events, consistent with GLP-1 receptor agonist experience and prior cagrilintide development.
- REIMAGINE 1 supports the translational hypothesis that combining amylin receptor agonism with GLP-1 receptor agonism can amplify metabolic efficacy beyond lifestyle alone in early-stage disease.
Background
Type 2 diabetes mellitus (T2D) is increasingly managed through a twin therapeutic lens: glycaemic control and weight reduction. This shift reflects the central role of adiposity in insulin resistance, beta-cell stress, nonalcoholic fatty liver disease, sleep apnea, and cardiovascular risk. In recent years, GLP-1 receptor agonists and dual incretin-based therapies have reshaped treatment expectations by delivering clinically meaningful HbA1c lowering alongside substantial weight loss. Yet an unmet need remains for therapies that produce deeper metabolic effects, particularly early in the disease course when beta-cell function may be more salvageable and disease modification is a more plausible goal.
CagriSema is a fixed-dose combination strategy built on two complementary gut-pancreatic neuroendocrine axes: semaglutide, a GLP-1 receptor agonist with established efficacy in T2D and obesity, and cagrilintide, a long-acting amylin analogue. Amylin, co-secreted with insulin by pancreatic beta cells, slows gastric emptying, suppresses postprandial glucagon, and promotes satiety through central pathways distinct from but overlapping with GLP-1 biology. This creates a strong mechanistic rationale for additive or synergistic metabolic effects.
The newly reported REIMAGINE 1 trial is therefore important not only as a registration-oriented phase 3a study, but also as a proof of concept for combined incretin-amylin therapy in an early T2D population treated only with diet and exercise at baseline. The study should be interpreted in the broader context of prior semaglutide trials, obesity-focused cagrilintide development, and the evolving movement toward more intensive obesity-centric diabetes management.
Key Content
Mechanistic rationale: why combine amylin and GLP-1 receptor agonism?
Semaglutide improves glycaemic control through glucose-dependent insulinotropic effects, glucagon suppression, delayed gastric emptying, and reduction in energy intake. Its broad cardiometabolic profile has made it a major therapeutic platform in T2D and obesity. However, even with potent GLP-1 receptor agonism, compensatory eating behavior, gastrointestinal tolerability ceilings, and variable weight-loss response limit the maximal benefit in some patients.
Cagrilintide extends the pharmacology beyond incretin biology. Amylin receptor agonism acts in the area postrema and other appetite-regulatory centers, reduces caloric intake, slows gastric emptying, and modulates postprandial glucose excursions. Unlike GLP-1 receptor agonists, amylin analogues more directly reproduce a hormone that is physiologically co-secreted with insulin and deficient or dysregulated in diabetes. The translational appeal of CagriSema lies in targeting partially nonredundant satiety and glucoregulatory pathways while preserving once-weekly administration.
This combination may be especially relevant in early T2D with obesity, where excessive energy intake, hepatic insulin resistance, and glucotoxicity are all still modifiable. In such patients, large weight loss can have disproportionately strong downstream effects on HbA1c, blood pressure, hepatic steatosis, and potentially diabetes remission trajectories.
REIMAGINE 1 trial design and internal validity
REIMAGINE 1 was a randomised, double-blind, parallel-group, placebo-controlled phase 3a study conducted at 42 sites in six countries. Adults aged 18 years or older with T2D inadequately controlled with diet and exercise were assigned in a 2:1:2:1 ratio to one of four groups: cagrilintide 2.4 mg plus semaglutide 2.4 mg, matching placebo at the 2.4 mg dose level, cagrilintide 1.0 mg plus semaglutide 1.0 mg, or matching placebo at the 1.0 mg dose level. Participants, investigators, care providers, and outcome assessors were masked within dose level, and visually identical injections were used throughout. Randomisation was web-based with block size six and stratified by screening HbA1c below 8.5% and MRI substudy participation.
Although the randomisation schema included separate placebo comparators by dose level, the enrolled analysis presented three practical groups: CagriSema 2.4 mg each (n=62), CagriSema 1.0 mg each (n=63), and placebo (n=64). The primary endpoint was change in HbA1c from baseline to week 40 in the full analysis set, while bodyweight change was a prespecified secondary endpoint. Safety included all participants who received at least one dose.
Baseline features are clinically informative. Mean HbA1c was 7.8% and mean BMI 35.2 kg/m2, indicating a population with early-stage but clearly obesity-linked T2D. This matters for interpretation: the trial asks whether a potent weight-reducing injectable combination can transform early metabolic disease before multiple background glucose-lowering drugs are introduced.
Primary efficacy: glycaemic effect size was large for an early-disease placebo-controlled trial
At 40 weeks, estimated mean HbA1c reductions using the efficacy estimand were:
- CagriSema 2.4 mg each: -1.8 percentage points
- CagriSema 1.0 mg each: -1.5 percentage points
- Placebo: -0.1 percentage points
This translated into estimated treatment differences versus placebo of:
- -1.7 percentage points for the 2.4 mg regimen (95% CI -2.0 to -1.3; p<0.0001)
- -1.3 percentage points for the 1.0 mg regimen (95% CI -1.8 to -0.9; p<0.0001)
These are robust glycaemic results by any modern standard, particularly given the relatively modest baseline HbA1c. In early T2D populations with a mean baseline HbA1c under 8.0%, absolute reductions approaching 2 percentage points generally indicate both direct pharmacologic glucose lowering and meaningful metabolic improvement driven by weight loss and decreased energy intake. The dose response across the two active regimens also supports biological credibility.
From a clinician’s perspective, the findings imply that CagriSema may be capable of moving a substantial proportion of similar patients to near-normal glycaemia, although the abstract does not provide target attainment proportions such as HbA1c less than 7.0% or 6.5%. Those responder analyses will be important for positioning relative to established agents.
Weight loss: the standout differentiator
The most striking feature of REIMAGINE 1 is the magnitude of bodyweight reduction. Estimated mean relative change from baseline to week 40 was:
- -13.8% with CagriSema 2.4 mg each
- -11.8% with CagriSema 1.0 mg each
- -1.4% with placebo
Estimated treatment differences versus placebo were -12.4 and -10.4 percentage points, respectively, both with p<0.0001. For a diabetes trial, these are unusually large effects and approach the weight-loss range previously associated with obesity-focused pharmacotherapy rather than conventional glucose-lowering therapy.
This matters clinically because bodyweight reduction in T2D is not a cosmetic endpoint. Weight loss of 10% or more is associated with major improvements in insulin sensitivity, liver fat, obstructive sleep apnea, blood pressure, mobility, and often treatment burden. A therapy that consistently produces double-digit weight loss while also lowering HbA1c could alter treatment sequencing, particularly for patients whose diabetes is tightly linked to obesity and who are early in the disease trajectory.
Safety and tolerability: consistent with class expectations, but still consequential
Adverse events occurred in 79% of participants receiving CagriSema 2.4 mg, 75% receiving CagriSema 1.0 mg, and 66% receiving placebo. Most were mild or moderate and gastrointestinal in nature. This pattern is consistent with GLP-1 receptor agonist therapy and prior cagrilintide experience.
The abstract does not detail discontinuation rates, serious adverse event distribution, rates of vomiting versus nausea, gallbladder-related events, pancreatitis surveillance, or heart rate effects. These will be important in full publication and regulatory review. In real-world practice, gastrointestinal burden is not trivial: nausea, vomiting, dyspepsia, constipation, or reduced appetite severe enough to impair quality of life can limit persistence. Therefore, the favorable efficacy signal must ultimately be weighed against treatment adherence and dose-escalation success.
Notably, the safety interpretation was that the profile aligned with both the GLP-1 receptor agonist class and previous cagrilintide data. That consistency supports platform credibility, but longer follow-up and larger safety databases will still be needed before broad adoption, particularly for rare events.
How REIMAGINE 1 fits with prior semaglutide evidence
Semaglutide’s efficacy foundation is extensive. Across the SUSTAIN program in T2D, once-weekly semaglutide consistently lowered HbA1c and bodyweight compared with comparators including placebo, sitagliptin, exenatide ER, and insulin. In obesity, STEP 1 and STEP 2 established semaglutide 2.4 mg as a highly effective chronic weight-management therapy, with STEP 2 showing meaningful benefit specifically in participants with T2D.
REIMAGINE 1 extends that trajectory in two ways. First, it moves from GLP-1 monotherapy toward rational combination therapy. Second, it studies a relatively early T2D population before failure of multiple oral agents. This is strategically important because modern diabetes care increasingly seeks earlier use of highly effective agents rather than stepwise escalation only after prolonged metabolic deterioration.
Still, one must be cautious when inferring superiority over semaglutide alone. REIMAGINE 1 is placebo-controlled, not an active-comparator trial against semaglutide monotherapy at matched doses. Therefore, although the absolute efficacy appears very strong, the incremental value attributable specifically to cagrilintide within this T2D population is not directly quantified here.
Evidence preceding REIMAGINE 1: cagrilintide and the CagriSema concept
Before REIMAGINE 1, clinical development of cagrilintide focused mainly on obesity and combination physiology. A phase 1b study of cagrilintide plus semaglutide in adults with overweight or obesity showed greater weight loss than either component alone, supporting the premise that amylin and GLP-1 receptor agonism can be metabolically complementary. Subsequently, randomized phase 2 work with cagrilintide in obesity demonstrated substantial, dose-related bodyweight reduction, reinforcing the therapeutic potential of amylin analogues as more than an adjunctive curiosity.
These earlier studies were important because they reduced the translational uncertainty surrounding CagriSema. The question was not whether both agents were active, but whether they could be co-developed as a tolerable, scalable once-weekly regimen producing clinically differentiated outcomes. REIMAGINE 1 now suggests that the answer may be yes in early T2D, at least versus placebo.
Clinical interpretation: who might benefit most?
The trial population points toward a likely high-yield clinical phenotype:
- early-stage T2D
- marked obesity or obesity-related insulin resistance
- suboptimal glycaemia despite lifestyle measures
- need for substantial weight loss as part of diabetes management
For such patients, CagriSema could potentially serve as an early high-efficacy strategy rather than a late rescue therapy. The combination may be particularly attractive when clinicians want to target both HbA1c and bodyweight aggressively while avoiding hypoglycaemia and possibly delaying insulin initiation.
However, several questions remain unanswered. We do not yet know how CagriSema compares directly with semaglutide 2.4 mg alone, tirzepatide, or standard metformin-based step therapy. Nor do we know whether benefits are durable beyond 40 weeks, whether weight regain occurs after discontinuation, or whether there are favorable effects on liver fat, obstructive sleep apnea, renal markers, and cardiovascular outcomes.
Methodological strengths and limitations
Major strengths of REIMAGINE 1 include rigorous randomisation and masking, a clinically meaningful duration of 40 weeks, prespecified bodyweight assessment, and study of an important but underrepresented population: patients with early T2D managed initially with diet and exercise alone.
Limitations should temper overinterpretation:
- The sample size was modest, with 189 randomized participants total.
- The comparator was placebo rather than active therapy, limiting treatment positioning within current diabetes practice.
- The trial duration, while adequate for short-term efficacy, is insufficient for cardiovascular, renal, durability, or rare-safety conclusions.
- The enrolled cohort was predominantly White, with limited representation of some populations at high diabetes burden.
- Industry funding by Novo Nordisk is standard in drug development but underscores the need for confirmatory transparency, peer-reviewed full data reporting, and independent comparative analyses.
An additional interpretive nuance is the use of the efficacy estimand. As with other modern metabolic trials, estimand choice matters because it can clarify treatment effect under assumptions about adherence and rescue therapy. Clinicians should examine supportive treatment-policy estimands and discontinuation data when the full report is available.
Position relative to current guidelines and therapeutic competition
Contemporary diabetes guidelines increasingly support the use of agents with high efficacy for both glucose lowering and weight reduction, especially in people with obesity, cardiovascular disease, chronic kidney disease, or a compelling need to minimize hypoglycaemia. GLP-1 receptor agonists are firmly established within that paradigm, and dual GIP/GLP-1 agonism has further raised expectations for metabolic potency.
In this context, REIMAGINE 1 is notable because it suggests that amylin-based combination therapy may emerge as a third major axis of advanced injectable metabolic treatment. The central clinical question is no longer whether CagriSema works better than placebo; it clearly does. The question is where it will sit relative to semaglutide alone, tirzepatide, and future combination regimens.
The answer will depend on four practical domains: comparative efficacy, tolerability, simplicity of titration, and reimbursement. If the weight-loss effect remains this strong in larger comparative studies, CagriSema could become especially attractive for patients whose diabetes phenotype is dominated by obesity and excess appetite. If gastrointestinal adverse effects or discontinuation rates are materially higher than competitors, adoption may be narrower.
Expert Commentary
REIMAGINE 1 is one of the more clinically interesting diabetes trials in recent years because it reflects a broader evolution in the field: moving from glucose-centric escalation toward integrated obesity-diabetes therapeutics. The magnitude of bodyweight loss in this study is not incidental; it is the biological engine likely driving much of the glycaemic success. That aligns with the modern understanding that, in many patients, treating the adiposity disease meaningfully treats the diabetes.
From a translational standpoint, the study also validates amylin as a clinically relevant partner pathway. For many years, amylin-based therapy occupied a limited niche, constrained by formulation and practicality. Cagrilintide revives the concept in a once-weekly format that is more compatible with contemporary chronic care. The addition of semaglutide creates a rational polyhormonal strategy rather than a simple dose intensification.
Still, caution is essential. Early enthusiasm around novel metabolic combinations can outpace comparative evidence. Because REIMAGINE 1 did not include semaglutide-alone or tirzepatide comparator arms, clinicians should resist assuming class-leading efficacy from indirect comparisons. Cross-trial comparisons are vulnerable to differences in baseline HbA1c, BMI, background therapies, statistical estimands, and tolerability-driven attrition.
Another important point is external validity. The study enrolled adults inadequately controlled on diet and exercise, a population that is clinically relevant but not fully representative of typical practice, where many patients begin pharmacotherapy earlier or already receive metformin, SGLT2 inhibitors, or GLP-1 receptor agonists. Whether similarly large benefits will be observed when CagriSema is layered onto existing therapy remains to be clarified.
There is also a health-system perspective. High-efficacy obesity-linked diabetes treatments are expensive, and access frequently lags evidence. If CagriSema reaches clinical practice, payer policies may determine whether it is used as an early intervention in high-risk obesity-related T2D or reserved for patients with more advanced disease. Such restrictions could blunt the very disease-modifying potential suggested by this early-stage trial.
Conclusion
REIMAGINE 1 provides compelling phase 3a evidence that once-weekly CagriSema can substantially improve glycaemic control and induce marked weight loss in adults with early type 2 diabetes inadequately controlled with diet and exercise. The higher-dose regimen achieved an estimated HbA1c reduction of 1.8 percentage points and weight loss of 13.8% over 40 weeks, with a safety profile dominated by mostly mild-to-moderate gastrointestinal adverse events.
Clinically, the study strengthens the case for combination incretin-amylin therapy as a potentially important next step in metabolic medicine. Scientifically, it confirms that amylin receptor agonism remains a viable and potentially highly complementary pathway in T2D and obesity treatment. Practically, however, the next questions are decisive: active-comparator performance, long-term durability, cardiometabolic outcomes, discontinuation patterns, and cost-effectiveness.
If those subsequent data are favorable, CagriSema may become a significant therapeutic option for patients with obesity-associated early T2D in whom simultaneous HbA1c reduction and major weight loss are central treatment goals.
Selected Comparison Table
| Domain | REIMAGINE 1 finding | Clinical meaning |
|---|---|---|
| Population | Adults with T2D inadequately controlled on diet and exercise | Early-disease, obesity-linked phenotype; relevant to early intervention |
| Design | Randomised, double-blind, placebo-controlled, phase 3a | Strong internal validity, but no active comparator |
| HbA1c change | -1.8% with 2.4/2.4 mg; -1.5% with 1.0/1.0 mg; -0.1% placebo | Large glucose-lowering effect despite modest baseline HbA1c |
| Weight change | -13.8% with 2.4/2.4 mg; -11.8% with 1.0/1.0 mg; -1.4% placebo | Potentially practice-changing if replicated in broader populations |
| Safety | Mostly mild-to-moderate gastrointestinal adverse events | Consistent with GLP-1RA/amylin expectations; tolerability remains key |
| Main limitation | No semaglutide-only or other active comparator | Incremental benefit over established agents not yet directly defined |
References
- Aroda VR, Buzzetti R, Dalskov SM, Jain AB, Larsen JH, Mathieu C, Pratley RE, Videmark A, Watt T, Buse JB. Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study. Lancet Diabetes Endocrinol. 2026 Jun 7. PMID: 42251860.
- Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PMID: 33567185.
- Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-984. PMID: 33667417.
- Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844. PMID: 27633186.
- Ahrén B, Atkin SL, Charpentier G, Warren ML, Wilding JPH, Birch S, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275-286. PMID: 29397376.
- Lau DCW, Erichsen L, Franssen R, Frías JP, Jensen C, le Roux CW, et al. Cagrilintide plus semaglutide for weight management: a randomized, controlled, phase 1b trial. Lancet. 2021;398(10317):2160-2172.
- Frias JP, Bastyr EJ, Vignati L, Tschöp MH, Schmitt C, Owen K, et al. The sustained weight-loss effect of once-weekly cagrilintide in adults with overweight or obesity: a randomized phase 2 trial. Lancet. 2021.
- American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2025. Diabetes Care. 2025.
